Caribou Biosciences Inc (CRBU) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Caribou Biosciences Inc stock $0.85, price $0.45, upside +89.4%, quality 31 out of 100. Rating: strongly undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range $0.4123 – $30.29 · fair‑value band $0.5600 – $1.06 · the $0.4487 price screens below the $0.8500 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Caribou Biosciences in your weekly email
Every Wednesday you see whether Caribou Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company.
Show moreShow less
It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies.
The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma.
Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Stock analysis
Caribou Biosciences Inc (CRBU) currently trades at $0.4487, while our model-based Fair Value estimate is $0.8500, implying the stock looks roughly 47% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.5600 (bear) to $1.06 (bull), the price of $0.4487 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Caribou Biosciences Inc reported revenue of $11.2M in FY2025 versus $9.6M in FY2021, a compound +3.8%/yr. Reported net income was −$148M in FY2025.
Key figures
Market cap $45.3M Micro · P/S ratio 5.13 · EPS (TTM) $−1.03 · Return on equity −93.8% · Return on assets (EBIT) −40.3% (5-year average) · Operating margin −1,720% · Revenue (TTM) $9.4M · Revenue growth (YoY) −26.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).
What moves the price
The share trades about 82% below its 52-week high and 9% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 89%, CRBU screens cheaper than that median.
Fair Value models
Bear$0.5600Fair Value $0.8500Bull$1.06
Price $0.4487 · Upside +89.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, no officer or director bought or sold shares on the open market.
SaleTimothy P KellyChief Technology Officer2× since Feb 24, 2026: 9,375 shares, avg. $1.94$18,188Feb 25, 2026
SaleBarbara G McClungChief Legal Officer6,938 shares at $1.96$13,598Feb 24, 202610b5-1 plan
SaleRuhi Ahmad KhanChief Business Officer6,938 shares at $1.96$13,598Feb 24, 202610b5-1 plan
SaleTina M. AlbertsonChief Medical Officer1,066 shares at $1.96$2,089Feb 24, 202610b5-1 plan
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+11.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.0%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.6%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−292.2% (2020) → −1,220.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (85 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Negative
Recent news coverage is more negative than average.
Compare Caribou Biosciences Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score31 · Bottom 25%
Fair Value upside+89.4% · Top 25%
Profitability
Return on assets−84.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−26.9% · Bottom 25%
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Caribou Biosciences Inc (CRBU) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of $0.8500 versus a price of $0.4487, about +89% upside (undervalued).
What is the fair value of CRBU?
Our model-based fair value for Caribou Biosciences Inc is $0.8500 (as of Nov 9, 2026), built from audited fundamentals. The current price: $0.4487.
What is the quality score of CRBU?
Caribou Biosciences Inc has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Caribou Biosciences Inc (CRBU)?
Our model-based price target is the fair value of $0.8500 (as of Nov 9, 2026) from 1 valuation models. Cautious scenario $0.5600, optimistic scenario $1.06. It is a calculation from audited fundamentals, not an analyst target.
What is the Caribou Biosciences Inc stock forecast for 2026?
Our models put fair value at $0.8500, about +89% upside versus a price of $0.4487 (undervalued). Cautious scenario $0.5600, optimistic scenario $1.06. The calculation is refreshed regularly with new filings.
What is the revenue of Caribou Biosciences Inc (CRBU)?
Caribou Biosciences Inc reported trailing-twelve-month revenue of about $9.4M (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Caribou Biosciences Inc (CRBU)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Caribou Biosciences Inc it is $0.8500 per share (as of Nov 9, 2026), against a price of $0.4487. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Caribou Biosciences Inc stock overvalued or undervalued in 2026?
As of Nov 9, 2026, CRBU trades below its calculated fair value: price $0.4487, fair value $0.8500, a gap of about +89% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CRBU?
No. The price is what the market pays today ($0.4487); the fair value is what the company's own numbers justify ($0.8500). For Caribou Biosciences Inc the two are $0.4013 per share apart. That gap is exactly why we show both numbers side by side.
How much is Caribou Biosciences Inc worth?
The market values Caribou Biosciences Inc at about $45.3M (market capitalisation, as of Nov 9, 2026). Per share that is $0.4487; our models calculate a fair value of $0.8500 per share.
What do the bullish and bearish scenarios say about CRBU?
Our models span a range for Caribou Biosciences Inc: cautious scenario $0.5600, base $0.8500, optimistic $1.06 per share (as of Nov 9, 2026, price $0.4487). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Caribou Biosciences Inc (CRBU)?
Balance-sheet figures for Caribou Biosciences Inc (as of Nov 9, 2026): return on equity −93.8%, debt of 0.01 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is CRBU from its 52-week high?
Caribou Biosciences Inc trades at $0.4487, about 82% below its 52-week high of $2.43 and 9% above the low of $0.4123 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.8500 is for.
Which stocks are comparable to Caribou Biosciences Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Caribou Biosciences Inc stock attractive at the current price?
The data as of Nov 9, 2026: price $0.4487, calculated fair value $0.8500 (+89%), Quality Score 31/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CRBU calculated?
We run Caribou Biosciences Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.8500 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Caribou Biosciences Inc currently trades 47% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Caribou Biosciences Inc (CRBU)?
The closing price on Nov 6, 2026 was $0.4487. Our model-based fair value is $0.8500, about +89% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Caribou Biosciences Inc right now?
The large discount to fair value meets weak quality (31/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($0.5600). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.5600 to $1.06) leaves room in how you read the outcome.
Key figures of Caribou Biosciences Inc
How large is the market capitalisation of Caribou Biosciences Inc (CRBU)?
The market capitalisation of Caribou Biosciences Inc is $45.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Caribou Biosciences Inc (CRBU)?
The price-to-sales ratio of Caribou Biosciences Inc is 5.13 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Caribou Biosciences Inc (CRBU)?
Earnings per share at Caribou Biosciences Inc are $−1.03. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Caribou Biosciences Inc (CRBU)?
The return on equity (ROE) of Caribou Biosciences Inc is −93.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Caribou Biosciences Inc (CRBU)?
On an EBIT basis the return on assets of Caribou Biosciences Inc is −40.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Caribou Biosciences Inc (CRBU)?
The operating margin of Caribou Biosciences Inc is −1,720% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Caribou Biosciences Inc (CRBU)?
Revenue at Caribou Biosciences Inc is growing −26.9% versus a year earlier (3y avg −7.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Caribou Biosciences Inc (CRBU) generate?
The free cash flow of Caribou Biosciences Inc is −$112M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Caribou Biosciences Inc (CRBU) carry?
The net debt of Caribou Biosciences Inc is $14.9M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Caribou Biosciences Inc in the live analysis
One click puts Caribou Biosciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026
